Lomefloxacin - Novartis Ophthalmics
Alternative Names: OkacynLatest Information Update: 24 Oct 2021
At a glance
- Originator Abbott Japan
- Developer Novartis Ophthalmics
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Infectious conjunctivitis
Most Recent Events
- 28 Feb 2003 Dainabot has merged with Hokuriku Seiyaku to form Abbott Japan
- 03 Apr 2001 Launched for Conjunctivitis in Spain (Ophthalmic)
- 25 Aug 2000 Registered for Conjunctivitis in Spain (Ophthalmic)